Publications by authors named "H Adomat"
Currently available animal models for calcium oxalate kidney stones are limited in their translational potential. Particularly with increasing interest in gut microbiota involvement in kidney stone disease, there are limited animal models which can be used. As such, we have developed a novel diet-induced hyperoxaluria murine model which addresses some of the shortcomings of other currently available models.
View Article and Find Full Text PDFArticle Synopsis
- This study addresses the ongoing kidney shortage for transplantation in patients with end-stage renal disease (ESRD) by exploring tissue engineering as a potential solution.
- Researchers used pig kidneys, which are similar to human kidneys, and removed their cells through a process called decellularization to retain their structure.
- By infusing pig kidney cells and human red blood cells into these decellularized kidneys, the study shows promising results that could lead to increasing the availability of transplantable organs for ESRD patients.
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Endocr Relat Cancer
December 2023
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that is highly expressed in castration-resistant prostate cancer, can promote steroidogenesis by altering the expression profile of key steroidogenic enzymes.
View Article and Find Full Text PDFArticle Synopsis
- * kt-3283 showed greater effectiveness than existing FDA-approved drugs (olaparib and vorinostat) in killing Ewing sarcoma cells and causing significant DNA damage and cell cycle arrest.
- * The findings support further clinical trials for kt-3283, highlighting its potential as a promising dual-inhibition treatment strategy for Ewing sarcoma patients.
Abiraterone acetate is a cytochrome P450 17A1 (CYP17A1) inhibitor that is indicated for use in both castration-resistant and castration-sensitive prostate cancer patients. To manage the mineralocorticoid effects of CYP17A1 inhibition, a glucocorticoid such as dexamethasone is co-administered with abiraterone. The goal of the present study was to understand the effect of dexamethasone on the disposition of abiraterone.
View Article and Find Full Text PDF